HCM
ACHN

Highbridge Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Highbridge Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-61,500
Closed -$545K – 1930
2015
Q2 		$545K Buy
+61,500
New +$582K 0.01% 927

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Highbridge Capital Management's ACHN Position: Q2 2017 in Review

Highbridge Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q2 2017, closing a stake of 35,478 shares — an estimated $149K sold.

Highbridge Capital Management first reported a position in ACHN in Q3 2013 and held it in 9 quarters. The position peaked at $2.59M in Q2 2015. 129 funds tracked by Wall St. Rank hold ACHN as of Q2 2017.

  • Highbridge Capital Management reported no remaining Achillion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 35,478 Achillion Pharmaceuticals shares in Q2 2017, an estimated $149K.
  • Highbridge Capital Management first reported a position in Achillion Pharmaceuticals in Q3 2013 and held it in 9 quarters.
  • Highbridge Capital Management's Achillion Pharmaceuticals position peaked at $2.59M in Q2 2015.
  • 129 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.